<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049762</url>
  </required_header>
  <id_info>
    <org_study_id>0813-13-SMC</org_study_id>
    <nct_id>NCT02049762</nct_id>
  </id_info>
  <brief_title>Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy</brief_title>
  <official_title>Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thus far, no study has evaluated the impact on aspirin in addition to the newer and more
      potent P2Y12 inhibitors, among ACS patients and current guidelines recommend dual
      anti-platelet therapy consisting of aspirin and a novel P2Y12 inhibitor in this population.

      Objective The investigators goal is to examine the effect of aspirin in addition to new
      anti-platelet agent (ticagrelor\prasugrel) on platelet reactivity in comparison with placebo,
      among ACS patients treated percutaneously.

      Design The proposed study is a randomized-controlled, double blind trial, conducted among ACS
      patients treated percutaneously. Eligible patients will recruited during hospitalization due
      to ACS after percutaneous coronary intervention (PCI), and randomization by envelopes on 1:1
      basis will take place a month after the index event, at a follow-up visit at the cardiac
      clinic.

      Platelet function and Endothelial function tests will be taken a month after the index event,
      and at a 2 weeks periods following aspirin/placebo therapy, cross-over and return to
      open-label aspirin.

      End-points platelet function tests will be compared between aspirin and placebo therapy and
      before and after the cross-over.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Current knowledge and data support the use of dual anti-platelets for patients after acute
      coronary syndrome (ACS). Novel P2Y12 inhibitors have shown their superiority on clopidogrel
      in regarding morbidity and mortality, but at the cost of higher bleeding rates - even in
      lower doses of aspirin there is increase risk for gastrointestinal (GI) bleeding. In a
      geographical analysis of the PLATO trial it has been shown difference at outcome. When higher
      dose of aspirin were used, the superiority of ticagrelor was reduced.

      The use of platelet reactivity tests have been proved and acknowledged in their usefulness
      for gauging bleeding and ischemic risks. Few studies have shown that clopidogral is
      inhibiting not only the ADP activity, but also the arachidonic acid (AA) pathway that is
      considered aspirin specific pathway. Examining the effect of potent P2Y12 inhibitors in
      healthy volunteers have shown increased inhibition of the AA pathway. Not only that the
      adding of aspirin, have shown little effect on inhibition of AA pathway.

      It has been demonstrated that vascular endothelial function is inversely correlated to
      platelet reactivity in both individuals without established cardiovascular disease (controls)
      and acute myocardial infarction patients.

      Objective Our goal is to examine the effect (platelet function test and endothelial function)
      of aspirin while added to novel P2Y12 inhibitors treated ACS patients.

      Design The proposed study is a randomized-controlled, double blind trial, conducted among ACS
      patients treated percutaneously. Eligible patients will recruited during hospitalization due
      to ACS after percutaneous coronary intervention (PCI), and randomization by envelopes on 1:1
      basis will take place a month after the index event, at a follow-up visit at the cardiac
      clinic.

      Platelet function and Endothelial function tests will be taken a month after the index event,
      and at a 2 weeks periods following aspirin/placebo therapy, cross-over and return to
      open-label aspirin.

      Study end-points The primary end-point is platelet function tests in response to AA.
      Secondary end-points will include endothelial function and platelet reactivity according to
      the platelet activity and VerifyNow test in response to ADP and platelet activation Clinical
      outcomes including all-cause and cardiac mortality and hospitalizations, recurrent ischemia
      and stent thrombosis, and bleeding events along with blood transfusions, will be recorded as
      safety end-points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>one month</time_frame>
    <description>platelet reactivity in response to arachidonic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>platelet reactivity</measure>
    <time_frame>one month</time_frame>
    <description>platelet reactivity in response to ADP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical outcome</measure>
    <time_frame>two months</time_frame>
    <description>hospitalizations and mortality</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Platelet Function and Reactivity Tests</condition>
  <condition>Novel P2Y12 Inhibitors</condition>
  <arm_group>
    <arm_group_label>P2Y12 inhibitors and aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACS patients on novel P2Y12 inhibitors and aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P2Y12 inhibitors and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ACS patients on novel P2Y12 inhibitors and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.</description>
    <arm_group_label>P2Y12 inhibitors and aspirin</arm_group_label>
    <arm_group_label>P2Y12 inhibitors and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  ACS defined according to the 3rd universal definition of MI

          -  PCI therapy

        Exclusion Criteria:

          -  Indication for anticoagulant therapy

          -  ACS on new P2Y12 inhibitors treatment

          -  Contraindication to P2Y12 therapy

          -  Renal failure defined as creatinine ≥1.5 mg/dL

          -  Non-compliance

          -  Life-threatening extra-cardiac disease or malignancy with a life expectancy below 1
             year

          -  Inability to sign an informed consent

          -  Participation in another trial during the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomi Matezky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.</citation>
    <PMID>19717846</PMID>
  </reference>
  <reference>
    <citation>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.</citation>
    <PMID>17982182</PMID>
  </reference>
  <reference>
    <citation>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. Erratum in: N Engl J Med 2001 Nov 15;345(20):1506. N Engl J Med 2001 Dec 6;345(23):1716.</citation>
    <PMID>11519503</PMID>
  </reference>
  <reference>
    <citation>Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 2;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498. Epub 2011 Jun 27.</citation>
    <PMID>21709065</PMID>
  </reference>
  <reference>
    <citation>Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.</citation>
    <PMID>24076493</PMID>
  </reference>
  <reference>
    <citation>Hobson AR, Qureshi Z, Banks P, Curzen NP. Effects of clopidogrel on &quot;aspirin specific&quot; pathways of platelet inhibition. Platelets. 2009 Sep;20(6):386-90.</citation>
    <PMID>19811222</PMID>
  </reference>
  <reference>
    <citation>Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost. 2010 Mar;8(3):613-5. doi: 10.1111/j.1538-7836.2009.03714.x. Epub 2009 Dec 3.</citation>
    <PMID>19995405</PMID>
  </reference>
  <reference>
    <citation>Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011 Mar;9(3):552-61. doi: 10.1111/j.1538-7836.2010.04160.x.</citation>
    <PMID>21143373</PMID>
  </reference>
  <reference>
    <citation>Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011 Oct;9(10):2103-5. doi: 10.1111/j.1538-7836.2011.04453.x.</citation>
    <PMID>21812912</PMID>
  </reference>
  <reference>
    <citation>Warner TD, Armstrong PC, Curzen NP, Mitchell JA. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart. 2010 Nov;96(21):1693-4. doi: 10.1136/hrt.2010.205724.</citation>
    <PMID>20956485</PMID>
  </reference>
  <reference>
    <citation>Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bástida G, Rodrigo L, Santolaria S, Güell M, de Argila CM, Quintero E, Borda F, Piqué JM; Asociación Española de Gastroenterología. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006 Dec;55(12):1731-8. Epub 2006 May 10.</citation>
    <PMID>16687434</PMID>
  </reference>
  <reference>
    <citation>Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006 Oct 7;333(7571):726. Epub 2006 Sep 19.</citation>
    <PMID>16984924</PMID>
  </reference>
  <reference>
    <citation>Wang TY, Xiao L, Alexander KP, Rao SV, Kosiborod MN, Rumsfeld JS, Spertus JA, Peterson ED. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation. 2008 Nov 18;118(21):2139-45. doi: 10.1161/CIRCULATIONAHA.108.787143. Epub 2008 Nov 3.</citation>
    <PMID>18981304</PMID>
  </reference>
  <reference>
    <citation>Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of &quot;nuisance&quot; bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol. 2008 Dec 15;102(12):1614-7. doi: 10.1016/j.amjcard.2008.07.063. Epub 2008 Sep 27.</citation>
    <PMID>19064014</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Shlomi Matetzky</investigator_full_name>
    <investigator_title>Head of The Cardiac Intensive Care Unit</investigator_title>
  </responsible_party>
  <keyword>novel P2Y12 inhibitors</keyword>
  <keyword>aspirin</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

